Editorials

Continuous combined hormone replacement therapy and endometrial hyperplasia

Risk of developing cancer is very low

Papers p 239

The use of continuous combined hormone replacement therapy, consisting of an oestrogen and a progestogen taken daily by postmenopausal women, is increasing. Its possible benefits are the prevention of endometrial hyperplasia and reduction in the occurrence of endometrial bleeding with time. Daily exposure to oestrogen and progestin without a break may be more important than using oestrogen intermittently in prevention of disease. A major concern is the occurrence of endometrial cancer in women using cyclic or sequential hormone replacement with the progestin being given for either less than 10 days each month, 10-16 days each month, or every three months for 14 days. ^{1 2} The case-control studies indicate a significant increased risk in endometrial cancer with a reduction in the number of days of exposure to progestin. The use of continuous combined hormone replacement therapy not only does not increase the incidence of endometrial cancer but could even be protective compared with non-use of hormone replacement.³

Most clinical trials of continuous combined hormone replacement therapy have been for one year in order to obtain regulatory approval for the products.⁴ In some instances two and three years of use have been reported, but these data are limited.⁵ The end point in clinical trials is endometrial hyperplasia rather than endometrial cancer because of the low incidence of endometrial cancer in the general population. In clinical situations we assume that inhibition of endometrial hyperplasia implies endometrial protection. This assumption has been challenged recently, with a call for randomised prospective clinical trials to document the efficacy of progestins in preventing endometrial cancer.⁶

To date, all clinical trials of unopposed oestrogen at moderate and high doses have shown an increase in the incidence of endometrial hyperplasia, which is related to dose and duration.⁴ The same is true for endometrial cancer after use of unopposed oestrogen. ^{1 2} The rate of endometrial hyperplasia was no different for continuous combined hormone replacement and placebo in a Cochrane meta-analysis.⁴ With use of sequential hormone replacement, the rates of endometrial hyperplasia were no different from placebo, although there was an increase in the occurrence of hyperplasia after 24 months (odds ratio 4, 95% confidence interval 1.2 to 14.0).

Doctors are confronted with women who have taken continuous combined hormone replacement for several years and then experience endometrial bleeding and spotting. Assessment of these women has entailed ultrasound imaging of the endometrium, hysteroscopy, and endometrial assessment through biopsy. The accuracy of ultrasonography in diagnosing endometrial disease in these patients is open to question.⁷ The reason for this intensity of evaluation of the bleeding is that doctors have been trained to evaluate aggressively any endometrial bleeding in postmenopausal women. These investigations have usually failed to document any malignant cause of the bleeding in women taking continuous combined hormone replacement; rather, endometrial polyps or uterine fibroids seem to be the most common finding.

A paper in this issue (p 239) addresses the issue of limited published data in long term users of continuous combined hormone replacement by presenting a 5 year follow up of postmenopausal women taking a preparation of 2.0 mg oestradiol and 1.0 mg norethindrone acetate (Kliofem/Kliogest; Novo Nordisk, Denmark).⁸ The paper found no evidence of endometrial hyperplasia after five years of continuous combined hormone replacement therapy. Moreover, 75% of the women had a final endometrial assessment. This is noteworthy because the usual attrition rates in clinical trials are higher than that in this study.

These data are reassuring because they are in agreement with case-control studies that have documented a reduction in the incidence of endometrial cancer in women taking continuous combined hormone replacement therapy.^1-3 These data should, however, be taken in context with the formulation of oestrogen and progestin used in the studyoestradiol-17 and norethindrone. Other formulations of oestrogen and progestin may not result in the same outcome. This is a speculative statement, based on the fact that each progestin has a different biological profile. On the basis of biochemical parameters, norethindrone could be considered a more potent progestin than either medroxyprogesterone acetate or progesterone.⁹ To date endometrial morphology has been used to determine the safety of the progestin used with oestrogen in hormone replacement preparations. The end point in clinical trials has been the morphological changes seen in the endometrial tissue acquired through biopsy. The accuracy of the interpretation of the histology of the endometrium between pathologists has been questioned because of the discrepancies found in the interpretation of the endometrium in clinical trials.¹⁰

Better markers of endometrial stimulation and inhibition than that of histology alone are needed. Until these are available, we must rely on the pathological interpretation of the findings, as was done in this study, to reassure us that the endometrium is protected with continuous combined hormone replacement therapy. For clinicians this means that investigation of a woman taking continuous combined hormone replacement without bleeding is not required, and with bleeding and spotting the chances of finding a neoplasm are low to non-existent.

David F Archer, director, clinical research centre and professor of obstetrics and gynaecology. 

The Jones Institute for Reproductive Medicine 601 Colley Avenue, Norfolk, VA 23507 USA (archerdf{at}evms.edu)

Footnotes

David F Archer has received research grants support from Wyeth, Organon, Ortho, Schering-Plough, Solvay, TAP Pharmaceuticals, Novo Nordisk, and Besins for several clinical trials including many related to menopause. He is or has been a consultant to Wyeth, Organon, Novo Nordisk, Solvay, Schering-Plough, TAP, and Watson laboratories. He has received support as a speaker from Wyeth, Ortho, Organon, Novo Nordisk, and Solvay.